Repligen (RGEN) Tops Q2 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $176.94 -6.2%
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.79, $0.27 better than the analyst estimate of $0.52. Revenue for the quarter came in at $163 million versus the consensus estimate of $144.1 million.
GUIDANCE:
Repligen sees FY2021 revenue of $625-645 million, versus the consensus of $585.9 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Repligen (RGEN) PT Lowered to $20 at RBC Capital
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
